ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
69,439.93
0.16%
S&P 500
5,346.99
-0.11%
Dow Jones
38,798.99
-0.22%
US Dollar vs Yen
156.7275
0.02%
Brent Oil
79.395
0.00%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Viking Therapeutics Inc (VKTX)

  7. Viking Therapeutics Inc (VKTX) ニュース

VKTX

Viking Therapeutics (VKTX)

Viking Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:VKTX
日付受信時刻ニュースソース見出しコード企業名
2024/06/0420 : 10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VKTXViking Therapeutics Inc
2024/06/0420 : 05PR Newswire (US)Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)NASDAQ:VKTXViking Therapeutics Inc
2024/05/3105 : 03PR Newswire (US)Viking Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:VKTXViking Therapeutics Inc
2024/05/2306 : 12Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:VKTXViking Therapeutics Inc
2024/05/2305 : 33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VKTXViking Therapeutics Inc
2024/04/2505 : 05PR Newswire (US)Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VKTXViking Therapeutics Inc
2024/04/2420 : 31IH Market NewsU.S. Futures Display Mixed Results Amid Earnings, WTI and Brent Crude Prices Dip in June Futures TradingNASDAQ:VKTXViking Therapeutics Inc
2024/04/1805 : 05PR Newswire (US)Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024NASDAQ:VKTXViking Therapeutics Inc
2024/03/2620 : 03PR Newswire (US)Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735NASDAQ:VKTXViking Therapeutics Inc
2024/03/0509 : 54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
2024/03/0509 : 52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
2024/03/0506 : 52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VKTXViking Therapeutics Inc
2024/03/0506 : 45PR Newswire (US)Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:VKTXViking Therapeutics Inc
2024/03/0206 : 13Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VKTXViking Therapeutics Inc
2024/02/2910 : 50PR Newswire (US)Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common StockNASDAQ:VKTXViking Therapeutics Inc
2024/02/2807 : 21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VKTXViking Therapeutics Inc
2024/02/2806 : 19PR Newswire (US)Viking Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:VKTXViking Therapeutics Inc
2024/02/2721 : 04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VKTXViking Therapeutics Inc
2024/02/2721 : 03PR Newswire (US)Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with ObesityNASDAQ:VKTXViking Therapeutics Inc
2024/02/1010 : 59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
2024/02/1006 : 01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VKTXViking Therapeutics Inc
2024/02/0909 : 40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
2024/02/0909 : 38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
2024/02/0906 : 56Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VKTXViking Therapeutics Inc
2024/02/0906 : 33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VKTXViking Therapeutics Inc
2024/02/0807 : 33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VKTXViking Therapeutics Inc
2024/02/0807 : 24Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VKTXViking Therapeutics Inc
2024/02/0806 : 09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VKTXViking Therapeutics Inc
2024/02/0806 : 05PR Newswire (US)Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateNASDAQ:VKTXViking Therapeutics Inc
2024/02/0110 : 39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VKTX

最近閲覧した銘柄

NYSE
MCD
McDonalds
NYSE
BAC
Bank of America
NYSE
NKE
Nike
PM
XAUUSD
Gold vs US Dollar
FX
USDGBP
US Dollar vs Sterling
NYSE
JPM
JP Morgan Chase
USOTC
BASFY
BASF (QX)
NASDAQ
GOOGL
Alphabet
FX
USDJPY
US Dollar vs Yen
COIN
SOLUSD
Solana
USOTC
RHHBY
Roche (QX)
AMEX
XLE
Energy Select Sector SPDR
AMEX
XLF
Financial Select Sector
NASDAQ
AAPL
Apple
NYSE
XOM
Exxon Mobil
AMEX
SPY
SPDR S&P 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有